homeearnings NewsAarti Drugs expanding capacity in specialty chemicals; plan capex of Rs 125 cr in H2FY22

Aarti Drugs expanding capacity in specialty chemicals; plan capex of Rs 125 cr in H2FY22

Aarti Drugs reported Q2 earnings and it posted flat revenues on a yearly and sequential basis while margins remained under pressure. To discuss the earnings and its capex plans, CNBC-TV18 spoke to company's CFO, Adhish Patil.

By CNBC-TV18 Oct 28, 2021 2:01:16 PM IST (Published)

CNBCTV 18
Aarti Drugs reported Q2 earnings and it posted flat revenues on a yearly and sequential basis while margins remained under pressure. To discuss the earnings and its capex plans, CNBC-TV18 spoke to company's CFO Adhish Patil.
Talking about the revenue drivers and capex plans for the company, Patil said, "We already have a strong pipeline of products. We are introducing more anti-diabetic products and we are expanding our current range of anti-diabetic products too. We are expanding our capacities in specialty chemicals. All of this is lined up, so the capex is going on."
"Though the first half was a little bit slow because of this incessant rains in Gujarat and Maharashtra and also because of the second lockdown at the beginning of the year. Even then we have done Rs 77 crore of cash outflow, and probably another Rs 100-125 crore in the second half of the year. Maybe by next calendar year-end, we might be coming up with these new capacities."